Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E13.14 EPS (ttm)7.25 Insider Own0.10% Shs Outstand706.70M Perf Week1.13%
Market Cap67.32B Forward P/E7.73 EPS next Y12.32 Insider Trans0.00% Shs Float706.29M Perf Month6.47%
Income5.23B PEG0.89 EPS next Q2.70 Inst Own76.10% Short Float1.50% Perf Quarter-1.03%
Sales16.35B P/S4.12 EPS this Y4.80% Inst Trans-2.80% Short Ratio2.56 Perf Half Y5.38%
Book/sh14.22 P/B6.70 EPS next Y13.82% ROA14.40% Target Price97.00 Perf Year5.41%
Cash/sh13.19 P/C7.22 EPS next 5Y14.70% ROE72.10% 52W Range58.59 - 98.97 Perf YTD48.63%
Dividend- P/FCF8.84 EPS past 5Y26.50% ROI16.50% 52W High-3.44% Beta1.38
Dividend %- Quick Ratio3.30 Sales past 5Y18.70% Gross Margin96.20% 52W Low63.12% ATR1.15
Employees8852 Current Ratio3.40 Sales Q/Q15.40% Oper. Margin44.70% RSI (14)61.64 Volatility1.23% 1.36%
OptionableYes Debt/Eq1.97 EPS Q/Q51.60% Profit Margin32.20% Rel Volume0.48 Prev Close95.26
ShortableYes LT Debt/Eq1.97 EarningsJul 30 AMC Payout0.00% Avg Volume4.15M Price95.57
Recom2.80 SMA202.23% SMA502.03% SMA2009.66% Volume320,953 Change0.33%
Aug-19-19Downgrade Mizuho Buy → Neutral $103 → $100
May-03-19Downgrade Barclays Overweight → Equal Weight $102
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Aug-20-19 01:54PM  BMY Stock Plus Celgene Will Be A Top 5 Pharma But Should You Buy It? Investor's Business Daily
Aug-19-19 04:23PM  Why The 2 Biggest Biotech Stocks Were Just Hit With Downgrades Investor's Business Daily
10:24AM  Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer Zacks
06:00AM  5 Biggest New Drug Approvals Potentially on the Way in 2019 Motley Fool
Aug-18-19 09:00AM  How Big Is Celgene's Latest Good News? Motley Fool
Aug-16-19 10:42AM  Palatin's (PTN) to Report Q4 Earnings: What's in the Cards? Zacks
10:30AM  U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis Business Wire
10:25AM  UPDATE 2-FDA approves Celgene's bone marrow cancer treatment Reuters
09:58AM  REFILE-FDA approves Celgene's bone marrow cancer treatment Reuters
Aug-15-19 01:40PM  Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios Benzinga
12:50PM  Seth Klarman's Baupost Boosts Liberty, Reduces eBay
10:30AM  Agios Rides High on Tibsovo Sales Amid Acute Competition Zacks
09:17AM  Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat Zacks
Aug-14-19 09:00PM  5 Top Cancer-Fighting Stocks to Buy Now Motley Fool
07:26PM  Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter
08:34AM  Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals Zacks
04:51AM  Stocks - Tilray, Canada Goose, Luckin Coffee Fall Premarket
Aug-13-19 12:35PM  Top Stock Reports: Micron, Sinopec, Celgene & More Zacks
10:43AM  Mergers & Acquisitions Take Center Stage in Biotech Industry Zacks
01:04AM  JPMorgan Chase set to scoop record fee for Allergan sale Financial Times
Aug-12-19 12:10PM  Bristol-Myers Squibb Stock Has Upside But Mind the Risks InvestorPlace
Aug-09-19 10:04AM  Risk-Takers Have a Reasonable Shot with BMY Stock InvestorPlace
Aug-07-19 05:30PM  bluebird bio Prepares for Launch Motley Fool
09:32AM  Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO Zacks
Aug-06-19 09:10PM  Editas Medicine Remains on Track Motley Fool
03:45PM  The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund
03:37PM  Celgene Continues Growing While Waiting for its Acquisition to Close Motley Fool
11:23AM  Acceleron Pharma Inc (XLRN) Q2 2019 Earnings Call Transcript Motley Fool
10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
07:00AM  What You'll Want to Know About Acceleron Pharma's Q2 Update Motley Fool
02:29AM  Fear Around Bristol-Myers Squibb Stock is Starting to Fade InvestorPlace
Aug-05-19 10:18AM  ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat Zacks
09:18AM  Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2 Zacks
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Aug-02-19 11:12AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat Zacks
Aug-01-19 12:02PM  Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks
11:32AM  Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance Zacks
Jul-30-19 04:10PM  Celgene Offers Beat-And-Raise As Bristol Merger Looms Closer Investor's Business Daily
08:55AM  Celgene (CELG) Q2 Earnings and Revenues Surpass Estimates Zacks
07:55AM  Celgene stock up after earnings beat MarketWatch
07:47AM  Celgene Reports Q2 Earnings Beat, Raises Guidance Benzinga
07:30AM  Celgene Reports Second Quarter 2019 Operating and Financial Results Business Wire
05:37AM  [video]Celgene Posts Strong Second-Quarter Earnings, Raises Guidance
03:53AM  Celgene Earnings, Revenue Beat in Q2
Jul-29-19 03:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:10AM  Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene Business Wire
07:45AM  Celgene Rises as European Commission OKs Merger With Bristol-Myers
Jul-26-19 01:24PM  Hach Rose Schirripa & Cheverie LLP Announces $55 Million Settlement in Antitrust Class Action Against Celgene GlobeNewswire
09:27AM  5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2 Zacks
09:18AM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
Jul-25-19 06:23PM  Bristol-Myers Squibb Co (BMY) Q2 2019 Earnings Call Transcript Motley Fool
03:00PM  5 Things You Need to Know From Bristol-Myers Squibb's Q2 Earnings Update Motley Fool
01:06PM  Pharma giants eye 'period of change' as drug pricing talk heats up in DC Yahoo Finance
11:35AM  Celgene Is the Remedy for Bristol-Myers's Cancer Setback Bloomberg
11:16AM  Bristol-Myers earnings beat boosts stock MarketWatch
10:45AM  Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View Zacks
10:32AM  UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter Reuters
10:18AM  Bristol-Myers Rosy Outlook Trumps Trial Setback as Stock Gains Bloomberg
08:53AM  Bristol-Myers Squibb Stock Is Hit by Drug-Trial Data, but Earnings Could Still Triumph
07:00AM  Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise Reuters
05:39AM  Bristol-Myers Tops Q2 Profit Forecast, Boosts Guidance as Eliquis Impresses
Jul-24-19 09:25PM  Bristol-Myers Squibb trims earnings guidance on Celgene deal Financial Times
06:07PM  Bristol-Myers Squibb Stock Falls After Results of Cancer Treatment Study Disappoint
01:30PM  Block & Leviton Announces $55 Million Settlement in Antitrust Case Against Celgene GlobeNewswire
11:56AM  3 Ways to Play the Historic Bargain In Chinese Stocks InvestorPlace
11:34AM  What To Know About Jounce's Amended Licensing Deal With Celgene Benzinga
10:58AM  Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded Zacks
07:30AM  Celgene and the Multiple Sclerosis Association of America Bring MS MindShift Initiative and Brain Bulb Hot Air Balloon to Festival to Raise Awareness of Multiple Sclerosis and Brain Health Business Wire
07:15AM  Celgene, Bristol-Myers and AbbVie still to report earnings this week: Heres what to expect MarketWatch
07:08AM  The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index Benzinga
12:30AM  Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings? Zacks
12:15AM  Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q2 Earnings? Zacks
Jul-23-19 04:00PM  Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation GlobeNewswire
02:03PM  Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings InvestorPlace
12:53PM  Bristol-Myers Stock Is Too Cheap to Ignore
10:18AM  The AbbVie-Allergan Merger Is the Most Positive of the Pharma Deals
Jul-22-19 12:06AM  The Parnassus Fund Exits Mattel, Sells Alphabet
Jul-20-19 09:53AM  The Week Ahead In Biotech: Pharma Earnings Pick Up Pace Benzinga
Jul-19-19 04:57PM  Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings? Zacks
01:59PM  FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçets Disease Business Wire
Jul-18-19 04:13PM  These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger Investor's Business Daily
10:33AM  Celgene (CELG) to Report Q2 Results: Wall Street Expects Earnings Growth Zacks
08:51AM  UnitedHealth (UNH) Beats on Q2 Earnings, Guides Up for 2019 Zacks
Jul-17-19 12:02PM  Congress set to vote on repeal of 'Cadillac tax' Yahoo Finance Video
10:10AM  Why Celgene (CELG) Could Beat Earnings Estimates Again Zacks
Jul-15-19 05:59PM  J&J Submits BLA for Subcutaneous Formulation of Darzalex Zacks
05:50PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
03:16AM  Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal Bloomberg
Jul-14-19 09:00AM  3 Incredibly Cheap Healthcare Stocks Motley Fool
Jul-13-19 12:18PM  3 U.S. Stocks to Watch in July Motley Fool
10:26AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
07:26AM  Health care is one of the stock markets healthiest sectors right now MarketWatch
Jul-11-19 03:34PM  Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19? Zacks
03:00PM  4 Drug Stocks Getting Smashed InvestorPlace
11:16AM  FDA Accepts Sanofi's BLA for Myeloma Candidate to Review Zacks
Jul-10-19 01:54PM  Fred Hutch appoints execs from Amazon and Celgene to board American City Business Journals
08:41AM  Megadeals Enter Biotech Realm And 3 Other Trends To Watch In 2019 Investor's Business Daily
08:14AM  Will Patent Woes Boost Pharma Stock Megamergers Further? Zacks
Jul-09-19 05:50PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elkins David VEVP, CHIEF FINANCIAL OFFICERAug 01Option Exercise0.0024,947024,947Aug 05 04:00 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037502,209Jun 17 04:00 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
BARKER RICHARD WDirectorJun 15Option Exercise0.001,125013,673Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441041,861Jun 17 04:00 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375062,884Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037502,409Jun 17 04:00 PM
Haller Julia ADirectorJun 14Option Exercise0.0030002,034Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300062,509Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300039,420Jun 17 04:00 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0030001,834Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0048401,534Jun 17 04:00 PM
Friedman Michael ADirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 13Option Exercise0.00484039,120Jun 17 04:00 PM
MARIO ERNESTDirectorJun 13Option Exercise0.00484062,209Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
Haller Julia ADirectorJun 13Option Exercise0.0048401,734Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 03Option Exercise22.4724,666554,24524,666Jun 05 04:05 PM
Curran TerrieSEE REMARKSMay 02Option Exercise0.001,56309,483May 06 04:05 PM
VESSEY RUPERTSEE REMARKSMay 02Option Exercise0.006,731013,984May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 02Option Exercise0.0015,6080227,886May 06 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELMay 02Option Exercise0.001,56304,674May 06 04:05 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYMay 02Option Exercise0.001,563013,124May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM